Levothyroxine Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Effects of levothyroxine treatment on fertility and pregnancy outcomes in subclinical hypothyroidism: a systematic review and meta-analysis of randomized controlled trials
CONCLUSIONS: Pre-conceptional levothyroxine treatment does not improve fertility or decrease the incidence of miscarriages. However, further well-designed studies are needed for pre-conceptional treatment, especially in TSH >4.0 mU/L. Levothyroxine treatment during pregnancy had a positive effect on preterm birth; nevertheless, this was only applicable to subclinical hypothyroidism with TSH >4.0 mU/L.PMID:38368537 | DOI:10.1089/thy.2023.0546 (Source: Thyroid : official journal of the American Thyroid Association)
Source: Thyroid : official journal of the American Thyroid Association - February 18, 2024 Category: Endocrinology Authors: Akiko Sankoda Hitomi Suzuki Misa Imaizumi Ai Yoshihara Sakiko Kobayashi Miyuki Katai Katsuhiko Hamada Yoh Hidaka Aya Yoshihara Hannah Nakamura Sumihisa Kubota Maiko Kakita-Kobayashi Akira Iwase Takashi Sugiyama Erika Ota Naoko Arata Source Type: research

Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The "THESIS"* collaboration (* T reatment of H ypothyroidism in Europe by S pecialists, an I nternational S urvey)
CONCLUSIONS: The perception of patients' dissatisfaction reported by physicians seems lower than that described by hypothyroid patients in previous surveys. LT4+LT3 treatment is used frequently by thyroid specialists in Europe for persistent hypothyroid-like symptoms even if they generally attribute such symptoms to non-endocrine causes and despite the evidence of non-superiority of the combined over the LT4 therapy. Pressure by dissatisfied patients on their physicians for LT3-containing treatments is a likely explanation. The association of the therapeutic choices with the clinician demographic characteristics and geo-ec...
Source: Thyroid : official journal of the American Thyroid Association - February 18, 2024 Category: Endocrinology Authors: Roberto Attanasio Milo š Žarković Enrico Papini Endre V Nagy Roberto Negro Petros Perros Ersin Akarsu Maria Alevizaki G öksun Ayvaz Tomasz Bednarczuk Biljana Beleslin Eszter Berta Miklos Bodor Anna Maria Borissova Mihail Boyanov Camille Buffet Maria-C Source Type: research

Response to Xiang and Zhang re: “Active Surveillance Outcomes of Patients with Low-Risk Papillary Thyroid Microcarcinoma According to Levothyroxine Treatment Status”
Thyroid ®, Ahead of Print. (Source: Thyroid)
Source: Thyroid - February 13, 2024 Category: Endocrinology Authors: Akira Miyauchi Source Type: research

Thyroid disorders induced by immune checkpoint inhibitors
AbstractImmune checkpoint inhibitors (ICIs) are a revolutionary class of drugs that powerfully contribute to cancer therapy by harnessing the immune system to fight malignancies. However, their successful use as anti-cancer drugs is accompanied by a wide spectrum of immune-related adverse effects (irAEs), including endocrinopathies. Among them, thyroid dysfunction stands out as one of the most common endocrinopathies induced by ICI therapy and surfaces as a prominent concern. Destructive thyroiditis is the pathophysiological basis shared by the most common patterns of thyrotoxicosis followed by hypothyroidism and isolated ...
Source: Endocrine - February 12, 2024 Category: Endocrinology Source Type: research

55-Year-Old Woman With Acute Progressive Dyspnea
A 55-year-old woman presented to the emergency department for evaluation of a 1-week history of progressive dyspnea. Her medical comorbidities included obesity, hypothyroidism treated with levothyroxine, and obstructive sleep apnea (OSA). Recent past medical history included symptomatic COVID-19 infection with a mild persistent nonproductive cough and increase in her levothyroxine dose from 175 μg to 200 μg daily for symptomatic hypothyroidism. On review of systems, she endorsed lower extremity edema, orthopnea, watery nonbloody diarrhea, and heat intolerance. (Source: Mayo Clinic Proceedings)
Source: Mayo Clinic Proceedings - February 6, 2024 Category: Internal Medicine Authors: Manfred M. Kubler, Anthony H. Kashou, Nandan S. Anavekar Tags: Residents ’ Clinic Source Type: research

Monitoring thyroid function during amiodarone use
Br J Hosp Med (Lond). 2024 Jan 2;85(1):1-5. doi: 10.12968/hmed.2023.0214. Epub 2024 Jan 31.ABSTRACTAmiodarone is an antiarrhythmic drug used to treat cardiac tachyarrhythmias. It has many adverse effects, with thyroid dysfunction one of the most notable. Through various mechanisms, both thyrotoxicosis and hypothyroidism can occur secondary to amiodarone therapy. There are two types of amiodarone-induced thyrotoxicosis: type 1 occurs in those with pre-existing thyroid disease and is treated with thionamide, whereas type 2 occurs in those without and is treated with glucocorticoids. Patients with amiodarone-induced hypothyro...
Source: British Journal of Hospital Medicine - February 1, 2024 Category: Internal Medicine Authors: Priya Sharma Riyad Sheikh Nipuna Siribaddana Abilash Sathyanarayanan Devaka Fernando Vakkat Muraleedharan Source Type: research